Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IMC-41A10 |
| Synonyms | |
| Therapy Description |
IMC-41A10 is a monoclonal antibody that targets RON and inhibits binding of its ligand MSP, resulting in inhibition of downstream signaling and cell migration, and reduced growth of RON-expressing tumors (PMID: 16982759). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IMC-41A10 | IMC 41A10|IMC41A10 | RON Inhibitor 11 | IMC-41A10 is a monoclonal antibody that targets RON and inhibits binding of its ligand MSP, resulting in inhibition of downstream signaling and cell migration, and reduced growth of RON-expressing tumors (PMID: 16982759). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R over exp | colon cancer | predicted - sensitive | IMC-41A10 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, IMC-41A10 inhibited MST1R (RON) downstream signaling and migration of colon cancer cells in culture, and reduced tumor growth in MST1R-positive colorectal cancer xenograft models (PMID: 16982759). | 16982759 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|